Trevena (NASDAQ:TRVN – Get Free Report) is anticipated to post its results before the market opens on Wednesday, February 25th. Analysts expect Trevena to post earnings of $0.18 per share and revenue of $3.00 million for the quarter.
Trevena Price Performance
NASDAQ TRVN opened at $0.01 on Tuesday. The stock has a market capitalization of $10,644.90, a price-to-earnings ratio of 0.00 and a beta of 0.63. Trevena has a 1-year low of $0.00 and a 1-year high of $1.93. The business’s fifty day moving average price is $0.01 and its 200-day moving average price is $0.06.
Trevena Company Profile
Trevena, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of biased ligand G protein-coupled receptor (GPCR) selective medicines. By leveraging its proprietary bias-ligand technology platform, Trevena aims to create therapies that preferentially activate beneficial signaling pathways while minimizing engagement of pathways linked to adverse effects. The company’s research efforts target areas of high unmet medical need, including pain management, cardiometabolic disorders and central nervous system conditions.
The company’s lead compound, oliceridine (also known by its brand name OLINVEO), is a G protein-biased μ-opioid receptor agonist designed for the treatment of moderate to severe acute pain in the hospital setting.
See Also
- Five stocks we like better than Trevena
- Elon Musk already made me a “wealthy man”
- Elon’s Secret AI Partner?
- Silver $500? The “Deficit Math” says it’s possible.
- Elon Musk: This Could Turn $100 into $100,000
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
